KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Shares Outstanding (Diluted Average) (2016 - 2025)

Neogenomics (NEO) has disclosed Shares Outstanding (Diluted Average) for 14 consecutive years, with $128.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 1.14% year-over-year to $128.1 million, compared with a TTM value of $128.1 million through Dec 2025, up 1.14%, and an annual FY2025 reading of $128.1 million, up 1.14% over the prior year.
  • Shares Outstanding (Diluted Average) was $128.1 million for Q4 2025 at Neogenomics, roughly flat from $128.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $130.2 million in Q2 2021 and bottomed at $116.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $125.1 million, with a median of $125.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 20.73% in 2021, then dropped 4.91% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $120.0 million in 2021, then grew by 3.55% to $124.2 million in 2022, then grew by 1.03% to $125.5 million in 2023, then grew by 0.92% to $126.7 million in 2024, then rose by 1.14% to $128.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for NEO at $128.1 million in Q4 2025, $128.4 million in Q3 2025, and $127.9 million in Q2 2025.